Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage and treat food and metabolic-related diseases, including exocrine pancreatic insufficiency (EPI), today announced the launch of PACT-CP, a Patient-Centric Chronic Pancreatitis Registry study to better understand the unmet needs and therapeutic burden on patients with...

Click to view original post